Hyun A Lee Selected Research

YH12852

1/2021	A population pharmacokinetic-pharmacodynamic model of YH12852, a highly selective 5-hydroxytryptamine 4 receptor agonist, in healthy subjects and patients with functional constipation.
1/2021	YH12852, a Potent and Selective Receptor Agonist of 5-hydroxytryptamine, Increased Gastrointestinal Motility in Healthy Volunteers and Patients With Functional Constipation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hyun A Lee Research Topics

Disease

4	Neoplasms (Cancer) 01/2021 - 12/2016
2	Constipation 01/2021 - 01/2021
1	Gastroesophageal Reflux (GERD) 01/2022
1	Peptic Ulcer (Peptic Ulcers) 01/2022
1	Gout 11/2019
1	Anxiety Disorders (Anxiety Disorder) 02/2017
1	Seizures (Absence Seizure) 02/2017
1	Neuralgia (Stump Neuralgia) 02/2017

Drug/Important Bio-Agent (IBA)

3	SilverIBA 03/2018 - 12/2016
2	YH12852IBA 01/2021 - 01/2021
2	Serotonin (5 Hydroxytryptamine)IBA 01/2021 - 01/2021
2	p38 Mitogen-Activated Protein KinasesIBA 03/2018 - 12/2016
1	AcidsIBA 01/2022
1	PotassiumIBA 01/2022
1	YH4808IBA 01/2022
1	GC1118IBA 01/2021
1	prucaloprideIBA 01/2021
1	Monoclonal AntibodiesIBA 01/2021
1	Pharmaceutical PreparationsIBA 01/2021
1	ErbB Receptors (EGF Receptor)IBA 01/2021
1	Uric Acid (Urate)IBA 11/2019
1	URC102IBA 11/2019
1	Caspase 3 (Caspase-3)IBA 03/2018
1	AntioxidantsIBA 03/2018
1	GoldIBA 01/2018
1	Pregabalin (Lyrica)FDA Link 02/2017

Therapy/Procedure

1	Intravenous Infusions 01/2021